Peringatan Keamanan

Roxithromycin primarily causes gastrointestinal adverse events, such as diarrhoea, nausea, abdominal pain and vomiting. Less common adverse events include headaches, rashes, abnormal liver function values and alteration in senses of smell and taste.

Roxithromycin

DB00778

small molecule approved investigational withdrawn

Deskripsi

Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to erythromycin, azithromycin, or clarithromycin. It was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila. Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections.

Struktur Molekul 2D

Berat 837.0465
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 12 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Very rapidly absorbed and diffused into most tissues and phagocytes.

Metabolisme

Hepatic. Roxithromycin is only partially metabolised, more than half the parent compound being excreted unchanged. Three metabolites have been identified in urine and faeces: the major metabolite is descladinose roxithromycin, with N-mono and N-di-demethyl roxithromycin as minor metabolites. The respective percentage of roxithromycin and these three metabolites is similar in urine and faeces.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

695 Data
Ivabradine Ivabradine may increase the QTc-prolonging activities of Roxithromycin.
Lomitapide The metabolism of Lomitapide can be decreased when combined with Roxithromycin.
Eliglustat The metabolism of Eliglustat can be decreased when combined with Roxithromycin.
Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Roxithromycin.
Cisapride The serum concentration of Cisapride can be increased when it is combined with Roxithromycin.
Pimozide The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Roxithromycin is combined with Pimozide.
Terfenadine The serum concentration of Terfenadine can be increased when it is combined with Roxithromycin.
Cilostazol The metabolism of Cilostazol can be decreased when combined with Roxithromycin.
Colchicine The metabolism of Colchicine can be decreased when combined with Roxithromycin.
Iloperidone The metabolism of Iloperidone can be decreased when combined with Roxithromycin.
Retapamulin The metabolism of Retapamulin can be decreased when combined with Roxithromycin.
Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Roxithromycin.
Vardenafil The metabolism of Vardenafil can be decreased when combined with Roxithromycin.
Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Roxithromycin.
Zopiclone The metabolism of Zopiclone can be decreased when combined with Roxithromycin.
Lovastatin The metabolism of Lovastatin can be decreased when combined with Roxithromycin.
Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Roxithromycin.
Alprazolam The metabolism of Alprazolam can be decreased when combined with Roxithromycin.
Warfarin The serum concentration of Warfarin can be increased when it is combined with Roxithromycin.
Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Roxithromycin.
(R)-warfarin The serum concentration of (R)-warfarin can be increased when it is combined with Roxithromycin.
R,S-Warfarin alcohol The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Roxithromycin.
S,R-Warfarin alcohol The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Roxithromycin.
(S)-Warfarin The serum concentration of (S)-Warfarin can be increased when it is combined with Roxithromycin.
Midazolam The serum concentration of Midazolam can be increased when it is combined with Roxithromycin.
Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Roxithromycin.
Telaprevir The serum concentration of Telaprevir can be increased when it is combined with Roxithromycin.
Eluxadoline The serum concentration of Eluxadoline can be increased when it is combined with Roxithromycin.
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Roxithromycin.
Citalopram The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Citalopram.
Anagrelide The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Anagrelide.
Disopyramide The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Disopyramide.
Clemastine The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Clemastine.
Ibutilide The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Ibutilide.
Valproic acid The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Valproic acid.
Grepafloxacin The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Grepafloxacin.
Quinine The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Quinine.
Sotalol The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Sotalol.
Toremifene The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Toremifene.
Thioridazine The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Thioridazine.
Trovafloxacin The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Trovafloxacin.
Mifepristone The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Mifepristone.
Cocaine The risk or severity of methemoglobinemia can be increased when Roxithromycin is combined with Cocaine.
Procainamide The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Procainamide.
Arsenic trioxide The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Arsenic trioxide.
Escitalopram The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Escitalopram.
Domperidone The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Domperidone.
Sparfloxacin The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Sparfloxacin.
Halofantrine The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Halofantrine.
Bepridil The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Bepridil.
Paliperidone The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Paliperidone.
Lithium cation The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Lithium cation.
Temafloxacin The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Temafloxacin.
Zuclopenthixol The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Zuclopenthixol.
Tetrabenazine The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Tetrabenazine.
Asenapine The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Asenapine.
Artemether The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Artemether.
Lumefantrine The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Lumefantrine.
Glasdegib The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Glasdegib.
Deutetrabenazine The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Deutetrabenazine.
Macimorelin The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Macimorelin.
Terodiline The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Terodiline.
Imatinib The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Imatinib.
Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Roxithromycin.
Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Roxithromycin.
Erythromycin The serum concentration of Roxithromycin can be increased when it is combined with Erythromycin.
Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Roxithromycin.
Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Roxithromycin.
Ranolazine The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Roxithromycin.
Sulfisoxazole The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Roxithromycin.
Methadone The risk or severity of QTc prolongation can be increased when Methadone is combined with Roxithromycin.
Sulpiride The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Roxithromycin.
Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Roxithromycin.
Promazine The risk or severity of QTc prolongation can be increased when Promazine is combined with Roxithromycin.
Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Roxithromycin.
Droperidol The risk or severity of QTc prolongation can be increased when Droperidol is combined with Roxithromycin.
Chlorpromazine The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Roxithromycin.
Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Roxithromycin.
Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Roxithromycin.
Fluorouracil The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Roxithromycin.
Perflutren The risk or severity of QTc prolongation can be increased when Perflutren is combined with Roxithromycin.
Cinnarizine The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Roxithromycin.
Atropine The risk or severity of QTc prolongation can be increased when Atropine is combined with Roxithromycin.
Chloroquine The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Roxithromycin.
Adenosine The risk or severity of QTc prolongation can be increased when Adenosine is combined with Roxithromycin.
Pentamidine The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Roxithromycin.
Gadobenic acid The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Roxithromycin.
Carbinoxamine The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Roxithromycin.
Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Roxithromycin.
Nalidixic acid The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Nalidixic acid.
Cinoxacin The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Cinoxacin.
Granisetron The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Granisetron.
Ondansetron The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Ondansetron.
Levosimendan The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Levosimendan.
Mesoridazine The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Mesoridazine.
Desloratadine The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Desloratadine.
Lomefloxacin The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Lomefloxacin.
Dimenhydrinate The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Dimenhydrinate.
Primaquine The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Primaquine.
Papaverine The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Papaverine.

Target Protein

50S ribosomal protein L10 rplJ
ATP-dependent translocase ABCB1 ABCB1

Referensi & Sumber

Synthesis reference: Murali Krishna Madala, Suresh Babu Meduri, Ketan Dhansukhlal Vyas, Ashok Krishna Kulkarni, "Process for preparing erythromycin derivative, such as roxithromycin, from the corresponding oxime." U.S. Patent US6051695, issued September, 1998.
Artikel (PubMed)
  • PMID: 3323166
    Gentry LO: Roxithromycin, a new macrolide antibiotic, in the treatment of infections in the lower respiratory tract: an overview. J Antimicrob Chemother. 1987 Nov;20 Suppl B:145-52.
Link

Contoh Produk & Brand

Produk: 0 • International brands: 154
International Brands
  • Acevor — Help
  • Actirox — Active HC
  • Ai Luo Xin — Huashen Pharmaceutical
  • Allolide — Roman Industries
  • Ammirox — MacroPhar
  • Anti-Bio — Kon/Nos Leon
  • Ao Ge Shen — Jianfa Pharmaceutical
  • Aparox — Siza
  • Arbid — Hetero
  • Aroxe — Global

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul